SSRIs治疗重性抑郁障碍前后血清脑源性神经营养因子的变化

目的研究SSRIs治疗重性抑郁障碍(MDD)患者前后的血清脑源性神经营养因子变化及相关因素。方法收集符合DSM-Ⅳ重性抑郁障碍诊断标准的患者21例,均给予SSRIs系统抗抑郁治疗6周,治疗前后均采用HAMD24、HAMA评估抑郁焦虑症状,ELISA法检测血清BDNF水平。结果患者的HAMD24、HAMA及HAMD24各项因子分在治疗后均有明显改善,与治疗前相比差异有统计学意义(P<0.05或P<0.01);患者的血清BDNF水平明显升高(P<0.05);HAMD24总分、HAMA总分及各因子分的下降与血清BDNF水平的升高无明显相关(P>0.05)。结论 MDD患者治疗后血清BDNF水平可明显提高,但与临床症状的改善无明显相关。

Brain-derived neurotrophic factor in major depression before and after SSRIs therapy

Objective To explore the change of serum levels of brain-derived neurotrophic factor in major depression before and after SSRIs therapy.Methods 21 patients with major depressive disorder as the case group were enrolled in this study.The diagnosis criteria was according to diagnostic and Statistical Manual of Mental Disorders-Ⅳ（DSM-Ⅳ）.Patients were accepted standardized treatments by SSRIs for six weeks.Before and after therapy,the depression and anxiety severity was assessed with 24-Hamilton Rating Scale for Depression（HAMD24） and Hamilton Rating Scale for Anxiety（HAMA）.Enzyme Linked Immunosorbent Assay（ELISA） was used for the serum BDNF levels assay.Results After treatment,the psychopathic symptoms improved significantly（P〈0.05 or P〈0.01）.The levels of serum BDNF increased after treatment（P〈0.05）.There was no correlation between the increase of serum BDNF levels and recovery of symptoms（P〉0.05）.Conclusion The serum levels of MDD can increase after treatment,but with not much correlations to the recovery of clinical symptoms.